Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
- PMID: 16824151
- DOI: 10.1111/j.1399-0012.2006.00489.x
Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
Abstract
Two Six-month pilot studies were conducted in renal (n = 17) or liver (n = 15) transplant recipients to evaluate renal function after conversion from calcineurin inhibitor (CI)- to sirolimus (SRL)-based immunosuppression. After an SRL loading dose, doses were individualized to achieve whole blood trough levels of 10-22 ng/mL. Overall, serum creatinine did not change from baseline to six months post-conversion but an improvement from 219.9 to 201.4 micromol/L at three months was noted in renal transplant recipients (p < 0.05). Another finding was a numerical increase in the mean glomerular filtration rate (GFR) from 26.8 to 33.2 mL/min/1.73 m(2) at six months among liver transplant recipients (NS). All patients survived and all grafts were functioning at the end of the study. In conclusion, renal function remained stable, with a tendency towards improvement, after abrupt conversion from CI- to SRL-based therapy in renal or liver transplant recipients with moderate renal insufficiency.
Similar articles
-
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. doi: 10.1093/ndt/gfh957. Epub 2005 Jun 28. Nephrol Dial Transplant. 2005. PMID: 15985508
-
An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.Clin Transplant. 2005 Feb;19(1):130-6. doi: 10.1111/j.1399-0012.2004.00314.x. Clin Transplant. 2005. PMID: 15659146 Clinical Trial.
-
Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.Clin Transplant. 2004;18 Suppl 12:61-6. doi: 10.1111/j.1399-0012.2004.00220.x. Clin Transplant. 2004. PMID: 15217410
-
Cyclosporine-A-based immunosuppression and renal functional reserve in organ-transplant patients.Transplant Proc. 2004 Mar;36(2 Suppl):248S-250S. doi: 10.1016/j.transproceed.2003.12.040. Transplant Proc. 2004. PMID: 15041347 Review.
-
Clinical application of sirolimus in renal transplantation: an update.Transpl Int. 2005 Mar;18(3):261-77. doi: 10.1111/j.1432-2277.2004.00039.x. Transpl Int. 2005. PMID: 15730485 Review.
Cited by
-
Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation.Transplantation. 2018 Jul;102(7):1096-1107. doi: 10.1097/TP.0000000000002175. Transplantation. 2018. PMID: 29557907 Free PMC article.
-
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.J Transplant. 2014;2014:845438. doi: 10.1155/2014/845438. Epub 2014 Feb 25. J Transplant. 2014. PMID: 24719752 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous